PMID: 11921494Mar 30, 2002Paper

The effects of valsartan on insulin sensitivity in patients with primary hypertension

The Journal of International Medical Research
C TopM Danaci

Abstract

Insulin resistance is an important risk factor of cardiovascular disease. This study was performed to determine the effects of valsartan on insulin sensitivity in patients with primary hypertension. In this study, non-obese subjects with primary hypertension and a reference group of healthy subjects matched by age, sex and body mass index were evaluated; patients with any other causes of peripheral insulin resistance and hyperlipidaemia were excluded. The effect of valsartan on insulin resistance, assessed by homeostasis model assessment (HOMA-IR), fasting serum insulin levels, determined by radioimmunoassay, and fasting blood glucose concentrations, measured by the glucose oxidase method, were evaluated. All obtained data were evaluated by Pearson correlation analysis. Before valsartan treatment, the fasting serum insulin levels were significantly elevated in the 20 hypertensive patients with primary hypertension compared with the 20 subjects in the reference group (19.6 +/- 7.1 versus 8.7 +/- 1.9 microIU/ml). The fasting serum insulin levels correlated with HOMA-IR. Correlation analysis also showed a significant relationship between HOMA-IR and both systolic and diastolic blood pressures (r = 0.71 and r = 0.77, respectively)....Continue Reading

References

Apr 1, 1975·The Journal of Clinical Investigation·R A DeFronzoP J Davis
Feb 1, 1991·American Journal of Hypertension·M W BrandsJ E Hall
Mar 1, 1989·American Journal of Hypertension·J E HallH L Mizelle
Aug 6, 1987·The New England Journal of Medicine·E FerranniniS Bevilacqua
Mar 1, 1985·The Journal of Clinical Investigation·M ModanZ Fuchs
Sep 1, 1985·Hypertension·C P LucasG M Reaven
Jun 1, 2000·American Journal of Hypertension·K A Jamerson
Jul 24, 2001·Blood Pressure. Supplement·G G Belz
Oct 31, 2001·Blood Pressure. Supplement·T Unger

❮ Previous
Next ❯

Citations

Mar 29, 2005·Vascular Pharmacology·Nana GletsuKenneth E Bernstein
Oct 2, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·James E Frampton, Lesley J Scott
Oct 7, 2011·The Journal of Clinical Hypertension·Kevin E C MeyersVictor Shi
Apr 27, 2011·Journal of the American Academy of Nurse Practitioners·Margaret A Fitzgerald
Sep 17, 2005·The American Journal of Medicine·Prakash C Deedwania, Vivian A Fonseca
Dec 1, 2012·European Journal of Pharmacology·Kentarou UshijimaAkio Fujimura
Aug 30, 2005·Blood Pressure·Luis M RuilopeFaiez Zannad
Nov 17, 2009·Drugs·Henry R BlackRita Samuel
Aug 8, 2007·Journal of the Cardiometabolic Syndrome·Po Sing Leung, Marc de Gasparo
Apr 2, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Kenneth S Hershon

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.